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ABSTRACT
Background: Previous studies suggested that obesity and diabetes were correlated 
with breast cancer outcome. The aim of the present study was to investigate the 
prognostic effect of obesity and diabetes on the outcome of early breast cancer patients.
Materials and Methods: Overall, 841 early breast cancer patients were 
prospectively enrolled between January 2009 and December 2013. Study population 
was divided into four groups:  (1) patients without obesity or diabetes; (2) patients 
with only diabetes; (3) patients with only obesity; and (4) patients with both diabetes 
and obesity. Categorical variables were analyzed by the chi-square test and survival 
data by the log-rank test. 
Results:  At diagnosis, obese and diabetic patients were more likely to be older 
(p < 0.0001) and post-menopausal (p < 0.0001) and to have a tumor larger than 2 cm 
(p < 0.0001) than patients in groups 1–3. At univariate analyses, obese and diabetic 
patients had a worse disease-free survival (p = 0.01) and overall survival (p = 0.001) 
than did patients without obesity and diabetes. At multivariate analyses, the  
co-presence of obesity and diabetes was an independent prognostic factor for disease-
free survival (hazard ratio=2.62, 95% CI 1.23–5.60) but not for overall survival. 
Conclusions: At diagnosis, patients with obesity and diabetes were older, had 
larger tumors and a worse outcome compared to patients without obesity or diabetes. 
These data suggest that metabolic health influences the prognosis of patients affected 
by early breast cancer.
INTRODUCTION
The latest World Health Organization (WHO) report 
estimated breast cancer (BC) incidence in westernized 
countries at 89.7 per 100,000 women, which makes it 
the most common cancer among women [1]. The WHO 
estimated that, in 2014, 422 million adults were affected 
by diabetes, with a prevalence of 8.5% [2], and more 
than half a billion people were affected by obesity (body 
mass index [BMI] ≥ 30 kg/m2), with a global prevalence 
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of 15% in women older than 18 years [3]. Diabetes 
and obesity affect both the BC phenotype [4] and the 
prognosis of patients [5]. Metabolic health is currently a 
major issue in daily oncological practice because weight 
gain, and elevated blood levels of glucose [6], insulin [6], 
triglycerides [6, 7] and cholesterol [7] are common side 
effects of adjuvant treatment [7–11]. To date, few studies 
have analyzed the impact of BMI and diabetes on the 
outcome of breast cancer patients [12, 13].  The aim of the 
present prospective trial was to investigate the association 
between diabetes, obesity and the outcome in patients 
affected by early BC, in a Mediterranean population.
RESULTS
Demographic, clinical and pathologic 
characteristics
A total of 841 early breast cancer patients: 536 
(64%) without diabetes or obesity, 231 (27%) with obesity 
alone, 34 (4%) with diabetes alone, and 40 with diabetes 
and obesity (5%) were enrolled in this study. The baseline 
clinical and pathologic characteristics of the patients in 
each study group are summarized in Table 1. At diagnosis, 
women with diabetes and obesity versus the only diabetes, 
only obesity, and no obesity and no diabetes patients, 
were more likely to be older (mean age ± SD:66.3 ± 7.8, 
62.0 ± 10.6, 58.9 ± 11.4 and 52.3 ± 12.3, respectively, 
p < 0.0001), to be post-menopausal (postmenopausal rate: 
98%, 82 %, 77 % and 50%, respectively, p < 0.0001), 
and to have larger tumors (T1 rate: 37%, 47%, 49% and 
61%, respectively, p < 0.0001). No statistically significant 
differences were found in nodal status, tumor grade, stage, 
distribution of histological BC subtypes or type of neo- or 
adjuvant therapy administered in the four study groups.
Survival analysis
At a median follow-up of 58.9 months, 137 (14.6%) 
patients experienced tumor recurrences and 67 (7.4%) 
patients died from their disease.  5-year DFS and OS rates 
were 85.5% and 92.8%, respectively.  Interestingly, at 
univariate analysis, by pairwise comparison by log-rank 
test, diabetic and obese women were more likely to relapse 
and die from breast cancer than patients without obesity 
or diabetes.  In detail, DFS rates were 72.5% vs 86%; 
p = 0.01 and OS rates were 79.5% vs. 93.4% p = 0.001 in 
diabetic and obese patients versus patients without either 
of these two conditions. No difference in terms of pairwise 
comparison was observed for DFS and OS in patients with 
only obesity or only diabetes vs patients with no obesity 
and no diabetes (p = 0.4 and p = 0.8, respectively).  
In exploratory analyses, we analyzed DFS and OS 
rates according to the co-presence of obesity and diabetes 
(obese and diabetic patients) versus the absence of both or 
the presence of only one of the two diseases (normal, obese 
or diabetic patients) (Figure 1A and 1B). Interestingly, 
patients with obesity and diabetes had worse DFS and OS 
versus patients without either or with only one of these 
conditions. In detail, DFS rates were 85.3% vs. 72.5% 
(p = 0.02) and OS rates were 93.3% vs. 80.0% (p = 0.001), 
in patients without obesity or diabetes or with only obesity 
or only diabetes vs. patients with obesity and diabetes, 
respectively. 
At univariate analyses, tumor stage, molecular 
subtype and type of adjuvant therapy received were also 
significantly associated to DFS Table 2. In detail, DFS 
rates were 90.7% vs. 75.1% in patients with Stage I & IIA 
vs. Stage IIB, IIIA-IIIC BC (p < 0.0001); 88.3% vs. 87.2% 
vs. 84.0% vs. 60.5% vs. 80.8% in patients with luminal 
A-like vs. luminal B-like Her 2-negative vs. luminal B-like 
Her 2 positive vs. HER2 positive vs. triple negative BC 
(p < 0.0001) and 87.9% vs. 77. 5% vs. 80.8% in patients 
receiving no adjuvant therapy vs. neo- or adjuvant CHT 
and HT vs. neo- or adjuvant HT only (p < 0.002). For 
OS, the variables significant at univariate analyses were 
patients’ age, tumor stage, molecular subtype and type 
of neo- or adjuvant therapy received. Overall survival 
rates were 95.9% vs. 86.5% in patients younger than 55 
vs older than 55 years (p < 0.0001); 95.9% vs. 86.5% 
in patients with Stage I and IIA vs. Stage IIB, IIIA-IIIC 
BC (p < 0.0001); 93.5% vs. 94.8% vs. 92.3% vs. 86.5% 
vs. 86.2% in patients with luminal A-like vs. luminal 
B-like Her 2-negative vs. luminal B-like Her 2-positive 
vs. HER2-positive vs. triple negative BC (p = 0.02); 
and 94% vs. 90.6% vs. 86.2% in patients not receiving 
adjuvant therapy vs. neo- or adjuvant CT and HT vs. neo- 
or adjuvant HT only (p = 0.008).
A multivariate Cox regression analyses, adjusted for 
the variables that were significant at univariate analyses, 
showed that the co-presence of diabetes and obesity had 
an independent prognostic value for DFS (HR = 2.62, 95% 
CI 1.23–5.60, p = 0.01) but not for OS (HR = 2.52; 95% 
CI 0.97–6.58, p = 0.058) (Table 3). 
DISCUSSION
Here we demonstrate that obesity and diabetes 
are independent prognostic factors for DFS in patients 
affected by early breast cancer treated with standard neo- 
or adjuvant therapy. The risk of cancer recurrence was 
approximately three times higher in patients with diabetes 
and obesity than in patients who were neither obese nor 
diabetic. Obese and diabetic patients were also more likely 
to have larger tumors and to be postmenopausal. However, 
the distributions of tumor grade, neo- or adjuvant 
therapies and tumor molecular subtypes (based on IHC 
classification) were similar across the study subgroups.
It is unclear whether diabetes increases breast cancer–
specific mortality. Compared with their non-diabetic 
counterparts, patients with breast cancer and pre-existing 
diabetes have been described to present with more advanced 
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breast cancer at diagnosis and to receive less aggressive 
treatments [14–16] given their underlying comorbidities and 
the perceived risk of greater chemotherapy-related toxicity. 
The diabetic patients included in our study had larger tumors 
than did their not diabetic counterparts. However, treatment 
choices in our patient population were not affected by the 
preexisting diagnosis of diabetes and the presence of this 
disease alone did not change the outcome of patients.
Three meta-analyses have recently examined the 
relationship between BMI and survival in large numbers 
Table 1: Distribution of patients and clinical-pathological characteristics
No Diabetes 
and No obesity
(n = 536)
Only 
Obesity
 (n = 231)
Only
Diabetes
 (n = 34)
Diabetes AND 
Obesity
 (n = 40)
p-value
Characteristics
Age at diagnosis (mean ±SD) 52.3 ±12.3 58.9±11.4 62.0±10.6 66.3±7.8 < 0.0001
Age < 0.0001
   ≤ 55 yrs 341 (64) 80 (35) 11 (32) 4 (10)
   > 55 yrs 195 (36) 151 (65) 23 (68) 36 (90)
Menopause < 0.0001
   Post-menopause 268 (50) 177 (77) 28 (82) 39 ( 98)
   Pre-menopause 268 (50) 54 (23) 6 (18) 1 (2.)
Stage 0.06
   I and IIA 203 (39) 65 (30) 12 (38) 11 (29)
   IIB, IIIA-IIIC 153 (30) 64 (29) 10 (31) 14 (37)
Grading 0.25
   1 26 (5) 12 (5) 2 (6) 3 ( 8)
   2 230 (44) 80 (36) 17 (50) 12 (32)
   3 268 (51) 134 (59) 15 (44) 23 ( 60)
N 0.09
   N0 286 (55) 108 (49) 22 (65) 22 ( 58)
   N1 161 (31) 62 (28) 8 (23) 9 ( 24)
   N2 55 (10) 35 (16) 2 (6) 7 (18)
   N3 22 (4) 17 (7) 2 (6) 0
T 0.001
   T1 318 (61) 111 (49) 15 (47) 15 ( 37)
   T2 181 (35) 101 (45) 12 (37) 23 ( 58)
   T3-T4 24 (4) 14 (6) 5 (16) 2 (5)
Type of therapy administered 0.2
   No adjuvant  therapy 31 (6) 21 (10) 3 (9) 3 (8)
   Neo- or adjuvant CT ± HT  82 (17) 25 (12) 3 (9) 2 (5)
   Neo- or adjuvant HT only 381 (77) 165 (78) 26 (82) 32 (87)
Molecular subtypes* 0.9
   Luminal A like 203 (40) 86 (38) 13 (38) 14 (37)
   Luminal B like Her2 neg. 152 (30) 70 (31) 11 (32) 13 (34)
   Luminal B like Her2 pos. 63 (12) 25 (11) 5 (15) 6 (16)
   Her2 positive 28 (5) 12 (5) 0 2 (5)
   Triple negative 66 (13) 34 (15) 5 (15) 3 (8)
CT: chemotherapy;   HT: hormone therapy;  *St Gallen categorization 2013:   Luminal A like: er+;pgr>=20; Her2-; ki67<20; 
Luminal B like Her2 neg.: er+;pgr<20 or ki67>=20; Her2-;   Luminal B like Her2 pos.: er+;pgr+; Her2+; ki67 any;   Her2positive: 
er-;pgr-; Her2+; ki67 any ;   Triple negative: er-;pgr-; Her2-; ki67 any. 
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of patients [17–19]. Overall, obesity was found to be 
associated with an increased risk of recurrence and death 
of approximately 35% to 40% after adjusting for tumor-
related variables, regardless of menopausal or hormone 
receptor status [17–19]. Consistently, Ligibel et al. [20] 
showed that each five-unit increase in BMI was associated 
with an increase in the risk of cancer recurrence and death, 
or of death alone, of approximately 8%. Differently from 
these data, we did not find any significant association 
between the weight of patients and breast cancer outcome. 
Discrepancies between our study and other studies may 
be due to differences in the length of follow-up and in 
the patient populations analyzed. Moreover, we found 
that 48% of our patients with BMI < 30, were overweight 
Figure 1: (A) Disease free survival (DFS) according to the co-presence of obesity and diabetes (obese and diabetic patients) versus the 
absence of both or the presence of only one of the two diseases (normal, obese or diabetic patients). (B) Overall survival (OS) according 
to the co-presence of obesity and diabetes (diabetes and obesity patients) versus the absence of both or the presence of only one of the two 
diseases (normal, obese or diabetic patients). Abbreviations: pts = patients.
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(BMI > 25 but ≤ 30) and this may have affected the 
overall prognosis of non obese patients. It is possible that 
underlying insulin resistance and diabetes may have further 
worsened prognoses in obese patients included in the 
afore-mentioned meta-analyses [17–19]. Neither glucose 
nor insulin level was considered in many of the previously 
reported trials included in the considered. [17, 19] 
Although, neither diabetes nor obesity affected the 
outcome of our patients, DFS was significantly worse 
in patients with these two conditions than in patients 
without them. This result was unrelated to tumor stage, 
tumor subtype, age and type of neo- or adjuvant therapy 
received. Our data suggest that diabetes and obesity alone 
does not necessarily predict metabolic health (defined as 
no components of the insulin resistance syndrome) and 
patients who are more metabolically unhealthy (such as 
obese patients with diabetes) may experience increased 
breast cancer recurrence. 
Our study and other studies support the hypothesis 
that the detrimental outcome in obese women results 
mainly from either the presence of insulin resistance 
and/or diabetes. In fact, Contiero et al. [21] (2013), in a 
retrospective investigation of 1261 women previously 
treated for breast cancer (stages I-III), did not find a 
significant association between BMI ≥ 25 and death from 
any cause (HR = 1.6, CI 0.88–1.53) irrespective of blood 
glucose levels. Larsen et al. [22] (2015) in a study of 
1,250 postmenopausal breast cancer patients did not find a 
significant association between overweight or obesity and 
risk of death from all causes (HR = 0.95, CI 0.72–1.22; 
HR = 1.09, CI 0.78–1.51, respectively) when diabetes 
was not included in the analyses. Finally, Herlevic et al. 
[23] (2015) in a retrospective study of 523 patients with 
invasive breast cancer did not find a significant association 
of overweight or obesity alone with OS (p = 0.49) or DFS 
(p = 0.33). 
Obesity and diabetes are both associated with 
peripheral tissue insulin resistance, which results in an 
increase of insulin levels to overcome this peripheral 
resistance. Insulin, and the insulin like growth factor 
1 (IGF1), increase estrogen levels by reducing the 
concentration of the sex hormone binding protein [24–26] 
and by enhancing the expression of the aromatase in adipose 
tissue [27]. Moreover, cross-talk was demonstrated between 
the IGF1R and HER2 pathways in HER2-positive BC [28, 
29].  In pre-clinical BC murine models, diet-induced obesity 
Table 2: Disease-free survival and overall survival results: Univariate analysis
Variable DFS OS
No. 
of Events %
Log rank*
p-value
No. 
of Events %
Log rank
p-value
Combined Diabetes & Obesity 0.07 0.008
No Diabetes  and  No Obesity 74 86.0 34 93.4
Only Obesity 38 83.3 0.4 16 92.7 0.7
Only Diabetes 4 88.2 0.8 3 90.6 0.5
Diabetes AND Obesity 11 72.5 0.01 8 79.5 0.001
Age
   ≤ 55 yrs 64 86.5 0.2 20 95.9 < 0.0001
   > 55 yrs 72 93.6 47 89.5
Stage
   I & IIA 55 90.7 < 0.0001 25 95.9 < 0.0001
   IIB, IIIA - IIIC 70 75.1 39 86.5
Molecular subtypes* < 0.0001 0.02
   Luminal A like 45 88.3 25 93.5
   Luminal B like Her2 neg. 33 87.2 13 94.8
   Luminal B like Her2 pos. 17 84.0 8 92.3
   Her2 positive 15 60.5 5 86.5
   Triple negative 23 80.8 15 86.2
Type of therapy use 0.002 0.008
   No adjuvant therapy 78 87.9 38 94.0
   Neo- or adjuvant CT ±HT  32 77.5 13 90.6
   Neo- or adjuvant HT only 23 80.8 15 86.2
*Pairwise comparison using a log-rank test.
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caused tumor progression by enhancing mesenchymal cell 
lines and epithelial-to-mesenchymal transition (EMT) 
markers, while caloric restriction was associated with both 
suppression of mesenchymal and epithelial cell lines, and 
inhibition of the EMT [30]. In human mammary epithelial 
cells, the EMT was also associated with overexpression of 
the IGF1 receptor [31]. Therefore, the increase in insulin 
and IGF1 levels, present in both obese and diabetic patients 
[32], may facilitate the EMT and tumor progression.
Our study has some limitations. The patient cohort 
was relatively homogeneous in terms of race, education 
and social status (most patients were well educated, 
and employed or retired), and thus results may not be 
generalized to all early breast cancer survivors in other 
geographic areas. Furthermore, we investigated fasting 
glucose and have no data on other potentially relevant 
markers of glucose metabolism and insulin resistance, 
such as baseline insulin and insulin-like growth factor-I. 
Importantly, our sample size is relatively modest and, 
although we adjusted survival analyses for known 
prognostic factors, it is possible that other factors could 
influence the relationship between obesity, diabetes and 
prognosis. Consequently, our data should be considered 
“hypothesis-generating” and need further validation. 
Our study has several strengths: it is a prospective, 
bi-institutional study; the pre-treatment fasting serum 
glucose levels of each patient were analyzed by the central 
laboratory of the participating institute; and, we evaluated 
a more comprehensive information on patients’ metabolic 
profile by analyzing together both body weight and 
glucose levels. In conclusion, we report novel evidence 
in support of a link between obesity and diabetes and 
breast cancer outcome. Indeed, we show that diabetes 
combined with obesity affects the outcome of early breast 
cancer, which suggests that the impairment of metabolic 
health may be associated to worsening patient prognosis. 
These findings represent a major issue in oncology daily 
practice. Based on these findings, improving body weight 
and blood glucose while avoiding type 2 diabetes through 
lifestyle changes including diet and exercise is expected to 
improve survival in people with breast cancer.
MATERIALS AND METHODS
Study population and laboratory assays
Eight-hundred and forty-one early breast cancer 
patients consecutively treated at the National Cancer 
Institute “G. Pascale Foundation” and at the University 
Hospital of Naples Federico II, between January 2009 and 
December 2013 were included in the present study. For 
each patient we recorded body weight and height, BMI, 
fasting plasma glucose levels and tumor characteristics, 
namely, tumor size (T), nodal status (N), stage, estrogen 
receptor (ER) and progesterone receptor (PgR expression, 
grading (G), HER2/neu status and tumor proliferation 
measured by ki67 labeling. According to the American 
Society of Clinical Oncology-College of American 
Pathologists guidelines, ER and PgR status were assessed 
by immunohistochemistry (IHC): the cut-off value used to 
distinguish ER/PgR “positive” from ER/PgR “negative” 
was ≥ 1% ER/PR-positive tumor cells [33], while HER 
2 expression was considered positive when, within an 
area of tumor that amounts to > 10% of contiguous and 
homogeneous tumor cells, there was evidence of protein 
overexpression at IHC or gene amplification (HER2 copy 
number or HER2/CEP17 ratio by in situ hybridization 
based on counting at least 20 cells within the area) [34].
The proliferative index Ki67 was assessed according 
the Recommendations of the International Ki67 in 
Breast Cancer Working Group [35] and defined as the 
percentage, at IHC, of immune-reactive tumor cells out 
of the total number of cells. The percentage of positive 
cells per case was scored into 2 groups: “low”: < 20% 
(low proliferative activity) and “high”: ≥ 20% (high 
proliferative activity). The molecular subtypes of BC 
were identified and categorized according to the 13th St 
Gallen International Breast Cancer Conference (2013) 
Expert Panel [36]. The BMI, calculated as weight divided 
by height squared, was stratified according to the WHO 
classification (≤ 30 kg/m2 = overweight/normal; > 30 kg/
m2 = obese). Fasting plasma glucose levels were assessed 
from blood samples according to the NCEP ATP III 
Table 3: Adjusted Cox multivariate analysis of breast cancer risk for the combination of diabetes 
and obesity
DFS OS
HR* 95% CI p-value HR 95% CI p-value
No diabetes  and  no obesity 1 0.06** 1 0.08**
Only obesity 0.96 0.59–1.56 0.8 0.66 0.30–1.47 0.3
Only diabetes 0.92 0.28–2.99 0.9 1.67 0.48–5.75 0.4
Diabetes and obesity 2.62 1.23–5.60 0.01 2.52 0.97–6.57 0.058
*Adjusted for terms of age (continuous), Stage (IA & IIA; IIB, IIIA & IIIB), Molecular subtypes (Luminal A; Luminal B; 
Triple positive; Her2pos; Triple negative) and Therapy (No therapy/ Neoadj. or adj. CT ± HT/ Neoadj. or adj. HT only)  ** 
Wald Test.
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criteria [37] and categorized as follows: normoglycemia 
< 126 mg/dl; diabetes ≥ 126 mg/dl, according to the latest 
American Diabetes Association guidelines [38]. Women 
with normoglycemia at the time of the blood test who 
reported taking diabetic medications were allocated to the 
diabetes category.   Based on the presence of obesity and 
diabetes, patients were divided in four subgroups: patients 
without obesity or diabetes; patients with only diabetes; 
patients with only obesity; and patients with both diabetes 
and obesity. 
The study was approved by the Institutional Review 
Board of the University of Naples Federico II (IRB 
approval # 743/15) and participants provided written 
informed consent to participate. The records and data 
of patients were anonymized and de-identified prior to 
analysis.
Statistical analyses
Descriptive statistics for categorical data are 
provided in terms of absolute and relative frequencies. 
The non-normally distributed continuous variable age is 
described by mean and standard deviation. Associations 
between the combination of study groups and patients 
or tumor characteristics were evaluated using the 
Kruskal-Wallis test for age, and the chi-square test 
for all other categorical variables: menopausal status, 
stage, grading, nodal stage, tumor size, neoadjuvant and 
adjuvant therapy, molecular subtypes and patient-status. 
The outcome of patients was analyzed in terms of both 
disease-free survival (DFS: with local, contralateral and 
distant disease recurrence, and secondary primary tumors 
and death from any cause defined as the event) and 
overall survival (OS: with death from any cause defined 
as the event). Time-to-event data (median follow-up 58.9 
months, range 1–108 months) were analyzed using the 
Kaplan-Meier method and summarized using medians, 
95% confidence intervals (CI), and survival curves. 
Study groups were compared using log-rank tests. To 
evaluate whether the co-presence of diabetes and obesity 
constitutes an independent prognostic factor, we used 
Cox proportional hazards regression models adjusted for 
age (continuous), stage (I and IIA; IIB and IIIA-IIIC), 
molecular subtypes (Luminal A-like; Luminal B-like 
Her2-negative; Luminal B-like Her2-positive; Her2-
positive: ER/PgR absent; triple negative) and therapy (no 
adjuvant therapy/neo- or adjuvant chemotherapy (CHT) 
± hormone therapy (HT)/neo- or adjuvant HT only). 
The category “No obesity and No diabetes” served as 
the reference group for the calculations of hazard ratios 
(HR) and 95% CI. All statistical tests were two-sided, 
and p values below 0.05 were considered statistically 
significant (no adjustment of significance levels for 
multiple testing). Statistical analyses were performed 
using IBM® SPSS® Statistics, version 23 (IBM Corp., 
Armonk, NY, USA)
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